Global Cancer Vaccine Partnering Terms and Agreements 2010-2021

Publisher Name :
Date: 01-May-2021
No. of pages: 250
Inquire Before Buying

The Global Cancer Vaccine Partnering Terms and Agreements 2010-2021 report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in cancer vaccine partnering deals

Disclosed headlines, upfronts, milestones and royalties by stage of development

Cancer vaccine partnering contract documents

Top cancer vaccine deals by value

This report provides details of the latest Cancer Vaccine agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Cancer Vaccine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Vaccine partnering deals.

The report presents financial deal term values for Cancer Vaccine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Cancer Vaccine partnering field; both the leading deal values and most active Cancer Vaccine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 320 online deal records of actual Cancer Vaccine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Cancer Vaccine dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Cancer Vaccine dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Cancer Vaccine deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer Vaccine dealmaking with a brief summary followed by a comprehensive listing of Cancer Vaccine deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Cancer Vaccine partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Cancer Vaccine partnering deals signed and announced since Jan 2010. The chapter is organized by specific Cancer Vaccine technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Cancer Vaccine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Cancer Vaccine partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer Vaccine technologies and products.

Key benefits

Global Cancer Vaccine Partnering Terms and Agreements 2010-2021 provides the reader with the following key benefits:

In-depth understanding of Cancer Vaccine deal trends since 2010

Access to headline, upfront, milestone and royalty data

Detailed access to actual Cancer Vaccine contracts entered into by leading biopharma companies

Identify most active Cancer Vaccine dealmakers since 2010

Insight into terms included in a Cancer Vaccine partnering agreement, with real world examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Cancer Vaccine Partnering Terms and Agreements 2010-2021 is intended to provide the reader with an in-depth understanding and access to Cancer Vaccine trends and structure of deals entered into by leading companies worldwide.

Cancer Vaccine Partnering Terms and Agreements includes:

Trends in Cancer Vaccine dealmaking in the biopharma industry since 2010

Analysis of Cancer Vaccine deal structure

Access to headline, upfront, milestone and royalty data

Access to Cancer Vaccine contract documents

Leading Cancer Vaccine deals by value since 2010

Most active Cancer Vaccine dealmakers since 2010

In Global Cancer Vaccine Partnering Terms and Agreements 2010-2021, the available deals are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific therapy target

Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Cancer Vaccine Partnering Terms and Agreements 2010-2021 report provides comprehensive access to available deals and contract documents for over 320 Cancer Vaccine deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are sale sand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Cancer Vaccine Partnering Terms and Agreements 2010-2021 report provides the reader with the following key benefits:

In-depth understanding of Cancer Vaccine deal trends since 2010

Access to headline, upfront, milestone and royalty data

Detailed access to actual Cancer Vaccine contracts entered into by leading biopharma companies

Identify most active Cancer Vaccine dealmakers since 2010

Insight into terms included in a Cancer Vaccine partnering agreement, with real world examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Global Cancer Vaccine Partnering Terms and Agreements 2010-2021

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Cancer Vaccine dealmaking
2.1. Introduction
2.2. Cancer Vaccine partnering over the years
2.3. Most active Cancer Vaccine dealmakers
2.4. Cancer Vaccine partnering by deal type
2.5. Cancer Vaccine partnering by therapy area
2.6. Deal terms for Cancer Vaccine partnering
2.6.1 Cancer Vaccine partnering headline values
2.6.2 Cancer Vaccine deal upfront payments
2.6.3 Cancer Vaccine deal milestone payments
2.6.4 Cancer Vaccine royalty rates

Chapter 3 - Leading Cancer Vaccine deals
3.1. Introduction
3.2. Top Cancer Vaccine deals by value

Chapter 4 - Most active Cancer Vaccine dealmakers
4.1. Introduction
4.2. Most active Cancer Vaccine dealmakers
4.3. Most active Cancer Vaccine partnering company profiles

Chapter 5 - Cancer Vaccine contracts dealmaking directory
5.1. Introduction
5.2. Cancer Vaccine contracts dealmaking directory

Chapter 6 - Cancer Vaccine dealmaking by technology type

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 - Cancer Vaccine deals by company A-Z

Appendix 2 - Cancer Vaccine deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

Appendix 3 - Cancer Vaccine deals by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty

Appendix 4 - Cancer Vaccine deals by therapy area

Appendix 5 -Deal type definitions


About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Cancer Vaccine partnering since 2010
Figure 2: Active Cancer Vaccine dealmaking activity since 2010
Figure 3: Cancer Vaccine partnering by deal type since 2010
Figure 4: Cancer Vaccine partnering by disease type since 2010
Figure 5: Cancer Vaccine deals with a headline value
Figure 6: Cancer Vaccine deals with an upfront value
Figure 7: Cancer Vaccine deals with a milestone value
Figure 8: Cancer Vaccine deals with a royalty rate value
Figure 9: Top Cancer Vaccine deals by value since 2010
Figure 10: Most active Cancer Vaccine dealmakers since 2010
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events
  • Global Vaccine Partnering Terms and Agreements 2014-2020: Deal trends, players and financials
    Published: 01-May-2021        Price: US 3495 Onwards        Pages: 550
    The Global Vaccine Partnering Terms and Agreements 2014-2021: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in vaccine and adjuvant partnering deals Deal terms analysis Partnering agreement structure Partnering contract documents Top deals by value Most active dealmakers A......
  • Global Cancer Vaccine Partnering Terms and Agreements 2010-2021
    Published: 01-May-2021        Price: US 3495 Onwards        Pages: 250
    The Global Cancer Vaccine Partnering Terms and Agreements 2010-2021 report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in cancer vaccine partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Cancer vaccine partnering contract documents Top cancer vaccine deals by value This report provides deta......
  • Global Cervical Cancer Vaccine Sales Market Report 2021
    Published: 30-Apr-2021        Price: US 4000 Onwards        Pages: 106
    The global Cervical Cancer Vaccine market is segmented by company, region (country), by Type, and by User. Players, stakeholders, and other participants in the global Cervical Cancer Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by User for the period 2016-2027. Segment by Type - 2-Valent Vaccine - 4-Valent Vaccine ......
  • Post-pandemic Era - Global Peptide Cancer Vaccine Market 2016-2027, With Breakdown Data of Capacity, Sales, Production, Export, Import, Revenue, Price, Cost and Gross Margin
    Published: 12-Apr-2021        Price: US 3620 Onwards        Pages: 115
    Summary World trade was already slowing in 2019 before COVID 19 outbreak, weighed down by trade tensions and slowing economic growth, such as uncertainty generated from Brexit, the U.S.-China trade war, the Japan-South Korea trade war. Trade is expected to fall by between 13% and 32% in 2020 as the COVID 19 pandemic disrupts normal economic activity and life around the world, according to the study of WTO.The decline in exports has been mainly due to the ongoing glo......
  • (Post-pandemic Era) - Global Peptide Cancer Vaccine Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2016-2027
    Published: 12-Apr-2021        Price: US 3650 Onwards        Pages: 115
    Summary As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%. Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly opt......
  • (Post-pandemic Era) - Global Peptide Cancer Vaccine Market Assessment, With Major Companies Analysis, Regional Analysis, Breakdown Data by Application/Type 2021
    Published: 12-Apr-2021        Price: US 4860 Onwards        Pages: 90
    Summary This study analysis was given on a worldwide scale, for instance, present and historical Peptide Cancer Vaccine growth analysis, competitive analysis, and also the growth prospects of the major regions. The report gives an exhaustive investigation of this market at country & regional levels, and provides an analysis of the industry trends in each of the sub-segments, from production, revenue and consumption. A quantitative and qualitative analysis of the main players in re......
  • Global Peptide Cancer Vaccine Sales Market Report 2021
    Published: 31-Mar-2021        Price: US 4000 Onwards        Pages: 146
    The global Peptide Cancer Vaccine market is segmented by company, region (country), by Regions, and by Application. Players, stakeholders, and other participants in the global Peptide Cancer Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Regions and by Application for the period 2016-2027. Segment by Regions - USA - Europe - ......
  • 2020-2025 Global Dendritic Cell Cancer Vaccine Market Report - Production and Consumption Professional Analysis (Impact of COVID-19)
    Published: 30-Mar-2021        Price: US 3360 Onwards        Pages: 130
    Dendritic cells (DC) are one of the major antigen presenting cells found in lymphoid organs. The main functions of dendritic cells are antigen display and activation of T cells. Antigen display presents the characteristics of the pathogen to T cells for identification and elimination from the body. These cells have the ability to capture and process tumor antigens that activate the expression of lymphocyte costimulatory molecules. Therefore, it causes secretion of cytokines to elicit an immune r......
  • Global BCG Vaccine Sales Market Report 2021
    Published: 26-Mar-2021        Price: US 4000 Onwards        Pages: 132
    The global BCG Vaccine market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global BCG Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027. Segment by Type - Immune BCG - Therapy BCG Segment by Ap......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs